Filing Details
- Accession Number:
- 0001140361-18-004481
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-01 16:48:17
- Reporting Period:
- 2018-01-30
- Accepted Time:
- 2018-02-01 16:48:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1322505 | Albireo Pharma Inc. | ALBO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1600023 | Ltd Partners Phase4 | 1 Cavendish Place London X0 W1G 0QF | No | No | No | No | |
1687344 | Phase4 Ventures Iii Lp | 1 Cavendish Place London X0 W1G 0QF | No | No | No | No | |
1687418 | Ltd Partner General Iii Ventures Phase4 | 50 Lothian Road, Festival Square Edinburgh X0 EH3 9WJ | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-01-30 | 98,500 | $34.40 | 1,066,947 | No | 4 | S | Indirect | Held by Phase4 Ventures III GP LP |
Common Stock | Disposition | 2018-01-30 | 1,500 | $37.06 | 1,065,447 | No | 4 | S | Indirect | Held by Phase4 Ventures III GP LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | Held by Phase4 Ventures III GP LP |
No | 4 | S | Indirect | Held by Phase4 Ventures III GP LP |
Footnotes
- The number of securities reported represents an aggregate number of shares sold in multiple market transactions over a range of sale prices. The Reporting Persons undertake to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Persons at each separate price within the range.
- Sale prices range from $34.40 to $34.71, inclusive.
- Sale prices range from $36.60 to $37.43, inclusive.
- Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase 4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, PhD, and Charles Sermon are Directors of Phase4 Partners (the "Phase4 Directors"). Each of the Phase4 Directors, Phase4 Partners, Phase4 GP, Phase 4 GPLP and Phase4 III may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.